Rosuvastatin and Paxlovid Interaction Guidelines
Introduction to Statin Interactions
- The American Heart Association recommends that rosuvastatin be temporarily discontinued during the 5-day course of Paxlovid due to the risk of severe statin toxicity, including rhabdomyolysis, as ritonavir inhibits OATP1B1 and BCRP transporters, increasing rosuvastatin exposure by 19-fold 1
- The European Society of Cardiology notes that studies with similar ritonavir-boosted regimens demonstrated a significant increase in rosuvastatin exposure when combined with OATP1B1/BCRP inhibitors, creating an unacceptable risk for myopathy, rhabdomyolysis, and acute kidney injury 1
Clinical Management Strategy
- The American College of Cardiology recommends that patients temporarily stop rosuvastatin for the 5-day Paxlovid treatment course, then resume at the previous dose after completion, as the 5-day interruption poses minimal cardiovascular risk 2
- The National Lipid Association advises that patients be counseled that temporary statin interruption is safer than risking severe muscle toxicity, and that they should monitor for muscle symptoms, such as pain, weakness, and dark urine, for 2 weeks after resuming rosuvastatin 2, 3
Alternative Statin Options
- The Infectious Diseases Society of America recommends that if a patient absolutely requires continuous lipid-lowering during Paxlovid treatment, pravastatin or fluvastatin are the only acceptable alternatives, as they are not metabolized by CYP3A4 and have minimal transporter interactions 4
- The American Heart Association notes that atorvastatin requires significant dose reduction, to 10-20 mg maximum, if continuation is necessary, but carries higher risk than pravastatin or fluvastatin 4
Critical Pitfalls to Avoid
- The European Society of Cardiology warns that reducing rosuvastatin dose and continuing it during Paxlovid therapy is not recommended, as even low doses may reach toxic levels with ritonavir's 19-fold increase in exposure 1
- The American College of Cardiology advises that restarting rosuvastatin before completing the full 5-day Paxlovid course should be avoided, as overlapping therapy creates the interaction risk, and that all other medications should be checked for potential interactions with Paxlovid 4